LRRK2 inhibitors and their potential in the treatment of Parkinson’s disease: current perspectives
Clinical Pharmacology: Advances and Applications · 2016
DOI: 10.2147/cpaa.s102191 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Pharmacology: Advances and Applications, 2016. Verfasst von Farzaneh Atashrazm und 1 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience Research Australia, Randwick. Die Arbeit wurde bisher 32-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Neuroscience Research Australia, Randwick.
- School of Medical Sciences, Faculty of Medicine, University of New South Wales, Kensington, NSW, Australia.
Zitieren
APA
Atashrazm, F., & Dzamko, N. (2016). LRRK2 inhibitors and their potential in the treatment of Parkinson’s disease: current perspectives. Clinical Pharmacology: Advances and Applications. https://doi.org/10.2147/cpaa.s102191
Vancouver
Atashrazm F, Dzamko N. LRRK2 inhibitors and their potential in the treatment of Parkinson’s disease: current perspectives. Clinical Pharmacology: Advances and Applications. 2016. doi:10.2147/cpaa.s102191
BibTeX
@article{Atashrazm2016,
author = {Atashrazm, Farzaneh and Dzamko, Nicolas},
title = {LRRK2 inhibitors and their potential in the treatment of Parkinson’s disease: current perspectives},
journal = {Clinical Pharmacology: Advances and Applications},
year = {2016},
doi = {10.2147/cpaa.s102191}
}
EUVIMED